BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 21129254)

  • 1. [Effect of gemcitabine on granulocyte colony-stimulating factor receptor and bcr/abl mRNA in patients with chronic myeloid leukemia].
    Liu D; Wang F; Sun L; Liu LX; Liu YF; Ling Z; Han XF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1168-71. PubMed ID: 21129254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. G-CSF and GM-CSF concentrations and receptor expression in peripheral blood leukemic cells from patients with chronic myelogenous leukemia.
    Lee J; Kim Y; Lim J; Kim M; Han K
    Ann Clin Lab Sci; 2008; 38(4):331-7. PubMed ID: 18988925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
    Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
    Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
    Skórski T; Szczylik C; Malaguarnera L; Calabretta B
    Folia Histochem Cytobiol; 1991; 29(3):85-9. PubMed ID: 1794439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
    Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The malignancy suppression role of miR-23a by targeting the BCR/ABL oncogene in chromic myeloid leukemia.
    Xishan Z; Xianjun L; Ziying L; Guangxin C; Gang L
    Cancer Gene Ther; 2014 Sep; 21(9):397-404. PubMed ID: 25213664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation.
    Zhang JG; Lin F; Chase A; Goldman JM; Cross NC
    Blood; 1996 Mar; 87(6):2588-93. PubMed ID: 8630427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.
    Ye YX; Zhou J; Zhou YH; Zhou Y; Song XB; Wang J; Lin L; Ying BW; Lu XJ
    Asian Pac J Cancer Prev; 2014; 15(22):9961-6. PubMed ID: 25520136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
    Zhang X; Ren R
    Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate.
    Jørgensen HG; Copland M; Allan EK; Jiang X; Eaves A; Eaves C; Holyoake TL
    Clin Cancer Res; 2006 Jan; 12(2):626-33. PubMed ID: 16428509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular analysis of hematopoietic colonies derived from chronic myeloid leukemia patients: interphase fluorescence in situ hybridization compared with RT-PCR.
    Thijsen SF; Schuurhuis GJ; van Oostveen JW; Theijsmeijer AP; Langenhuijsen MM; Ossenkoppele GJ
    Leukemia; 1997 Feb; 11(2):301-5. PubMed ID: 9009097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of myeloid progenitor cells expressing BCR-ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Pichert G; Alyea EP; Soiffer RJ; Roy DC; Ritz J
    Blood; 1994 Oct; 84(7):2109-14. PubMed ID: 7919323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C/EBPβ promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion.
    Hayashi Y; Hirai H; Kamio N; Yao H; Yoshioka S; Miura Y; Ashihara E; Fujiyama Y; Tenen DG; Maekawa T
    Leukemia; 2013 Mar; 27(3):619-28. PubMed ID: 22948537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin Е activates expression of С/EBP alpha transcription factor and G-CSF receptor in leukemic K562 cells.
    Shvachko LP; Zavelevich MP; Gluzman DF; Kravchuk IV; Telegeev GD
    Exp Oncol; 2018 Dec; 40(4):328-331. PubMed ID: 30593760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Influence of IFN-alpha and IFN-alpha combined with GM-CSF on expression of the genes related to cell apoptosis of MNCs from bone marrow in CML patients].
    Tang LJ; Chen HC; Peng XH
    Hunan Yi Ke Da Xue Xue Bao; 2000 Dec; 25(6):570-2. PubMed ID: 12516408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of beta-Catenin Gene in CML and its relationship with bcr/abl].
    Li ZJ; Qiu LG; Li X; Mai YJ; Wang GR; Yu Z; Wang YF; Li CH; Li Q
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):931-5. PubMed ID: 17956664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.
    Verfaillie CM; Bhatia R; Miller W; Mortari F; Roy V; Burger S; McCullough J; Stieglbauer K; Dewald G; Heimfeld S; Miller JS; McGlave PB
    Blood; 1996 Jun; 87(11):4770-9. PubMed ID: 8639848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of bcr-abl mRNA-expressing cells in long-term cultures established from chronic myeloid leukemic bone marrow or blood.
    Pasternak G; Pasternak L
    Ann Hematol; 1994 Jan; 68(1):9-14. PubMed ID: 8110881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.